(Q40960920)

25 September 2017

1 reference

title

Present status of biological response modifiers in cancer (English)

1 reference

25 September 2017

D R Parkinson

1

1 reference

PubMed ID

8585537

25 September 2017

language of work or name

English

0 references

publication date

1 December 1995

1 reference

American Journal of Medicine

25 September 2017

1 reference

25 September 2017

99

1 reference

25 September 2017

6A

1 reference

25 September 2017

54S-56S

1 reference

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

25 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980288-5

Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980288-5

Antitumor and antimetastatic activity of interleukin 12 against murine tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980288-5

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980288-5

Angiogenesis and breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980288-5

Antitumor effects of GBS toxin: a polysaccharide exotoxin from group B beta-hemolytic streptococcus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980288-5

10.1016/S0002-9343(99)80288-5

7 January 2021

Identifiers

DOI

1 reference

25 September 2017

1 reference

PubMed ID

8585537